Bumetanide analogue - NeuroPro Therapeutics
Alternative Names: NPT-2042Latest Information Update: 08 Aug 2025
At a glance
- Originator Neuropro Therapeutics
- Class Antidementias; Antiepileptic drugs; Small molecules
- Mechanism of Action Sodium-potassium-chloride symporter inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Absence epilepsy; Epilepsy
Most Recent Events
- 26 Jun 2025 NeuroPro Therapeutics completes a phase I trial for Reflex epilepsy in USA (PO) (NCT06525649)
- 11 Mar 2025 Phase-II clinical trials in Absence epilepsy (In adolescents, In adults, In the elderly, Treatment-experienced) in USA (PO) (NCT06769659)
- 11 Mar 2025 Phase-II clinical trials in Epilepsy (In adults, In adolescents, In the elderly, Treatment-experienced) in USA (PO) (NCT06769659)